Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06OFS
|
|||
| Former ID |
DIB006425
|
|||
| Drug Name |
Rilmenidine
|
|||
| Synonyms |
Rilmenidine phosphate; 85409-38-7; Rilmenidine dihydrogen phosphate; UNII-59QD64Q32M; EINECS 287-106-2; 59QD64Q32M; S 3341-3; 4,5-Dihydro-N-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1); 2-Oxazolamine, 4,5-dihydro-N-(dicyclopropylmethyl)-, phosphate (1:1); (Dicyclopropylmethyl)(4,5-dihydro-2-oxazolyl)ammonium dihydrogen phosphate; W-104082; 2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-, phosphate (1:1); N-(dicyclopropylmethyl)-4,5-dihydrooxazol-2-amine; phosphoric acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H16N2O
|
|||
| Canonical SMILES |
C1CC1C(C2CC2)NC3=NCCO3
|
|||
| InChI |
1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)
|
|||
| InChIKey |
CQXADFVORZEARL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 54187-04-1
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:8862
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-2C (ADRA2C) | Target Info | Modulator | [1], [2] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Reactome | Adrenoceptors | |||
| Adrenaline signalling through Alpha-2 adrenergic receptor | ||||
| Adrenaline,noradrenaline inhibits insulin secretion | ||||
| G alpha (i) signalling events | ||||
| G alpha (z) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Platelet Aggregation (Plug Formation) | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.